Show simple item record

dc.contributor.advisorTeo Forcht Dagi and Pedro Huertas.en_US
dc.contributor.authorKhan, Rehan A. (Rehan Abbas)en_US
dc.contributor.otherHarvard University--MIT Division of Health Sciences and Technology.en_US
dc.date.accessioned2008-09-03T14:53:47Z
dc.date.available2008-09-03T14:53:47Z
dc.date.copyright2007en_US
dc.date.issued2007en_US
dc.identifier.urihttp://hdl.handle.net/1721.1/42208
dc.descriptionThesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2007.en_US
dc.descriptionIncludes bibliographical references (leaves 71-73).en_US
dc.description.abstractThe leading publicly traded pharmaceutical companies ("Big Pharma) in the US are facing a commercial crisis - their sales structure collectively consisting of more than 100,000 pharmaceutical sales representatives, originally setup to launch blockbusters, is suffering as a result of shrinking pipelines and low NME approvals. Although sales and marketing constitutes by far the largest corporate expense at 33% of revenues, sales productivity continues to decline. The goal of this study is to explore how pharmaceutical sales will change over the next 5 - 7 years and more specifically explore the role technology (including the internet) will play in the sales process. The study focuses on testing the perceptions of two key stakeholders -pharmaceutical executives and current medical students (future physicians) regarding the future of pharmaceutical sales process. Accordingly, 33 individuals were interviewed of which 18 were pharmaceutical executives and 15 were future physicians. The study tests three hypotheses: 1. Pharma executives believe that sales representative based detailing will continue to be the predominant method to engage and sell to physician customers while future physicians believe that technology will play a dominant role in the pharmaceutical detailing process. 2. Pharmaceutical executives agree that the most effective and ethical method to convey the benefits and challenges of an ethical pharmaceutical product are via a trained sales representative while future physicians believe that the sales representative does not effectively and ethically convey the merits of the relevant pharmaceutical therapy. 3. Person to person contact is not essential in conveying the merits of a particular ethical therapy - pharmaceutical executives disagree with this premise while future physicians agree.en_US
dc.description.abstract(cont.) The data sets were compared using the following statistical tests: Yates' chi-square test, Armitage's chi-squared test and Two sample test of binomial proportions. In conclusion, the data showed that the perceptions of pharma executives and future physicians were in concurrence with each other.en_US
dc.description.statementofresponsibilityby Rehan A. Khan.en_US
dc.format.extent73 leavesen_US
dc.language.isoengen_US
dc.publisherMassachusetts Institute of Technologyen_US
dc.rightsM.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.en_US
dc.rights.urihttp://dspace.mit.edu/handle/1721.1/7582en_US
dc.subjectHarvard University--MIT Division of Health Sciences and Technology.en_US
dc.titleWhat future physicians want : a comparative analysis of the perception of medical students and pharmaceutical industry executives regarding the future of pharmaceutical salesen_US
dc.title.alternativeComparative analysis of the perception of medical students and pharmaceutical industry executives regarding the future of pharmaceutical salesen_US
dc.typeThesisen_US
dc.description.degreeS.M.en_US
dc.contributor.departmentHarvard University--MIT Division of Health Sciences and Technology
dc.identifier.oclc230824588en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record